Myriad Financial Statements From 2010 to 2025

MYGN Stock  USD 9.90  0.22  2.17%   
Myriad Genetics financial statements provide useful quarterly and yearly information to potential Myriad Genetics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Myriad Genetics financial statements helps investors assess Myriad Genetics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Myriad Genetics' valuation are summarized below:
Gross Profit
585.4 M
Profit Margin
(0.15)
Market Capitalization
924 M
Enterprise Value Revenue
1.1485
Revenue
837.6 M
We have found one hundred twenty available fundamental ratios for Myriad Genetics, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Myriad Genetics' last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to drop to about 835 M. In addition to that, Enterprise Value is likely to drop to about 790.3 M

Myriad Genetics Total Revenue

431.62 Million

Check Myriad Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Myriad Genetics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 74.7 M, Total Revenue of 431.6 M or Gross Profit of 338.4 M, as well as many indicators such as Price To Sales Ratio of 2.3, Dividend Yield of 0.22 or PTB Ratio of 4.16. Myriad financial statements analysis is a perfect complement when working with Myriad Genetics Valuation or Volatility modules.
  
Check out the analysis of Myriad Genetics Correlation against competitors.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Myriad Genetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets686.6 MB963.5 M
Slightly volatile
Short and Long Term Debt Total106.3 M174.9 M115.1 M
Slightly volatile
Other Current Liabilities7.1 M7.5 M55.2 M
Pretty Stable
Total Current Liabilities172.3 M164.1 M112.6 M
Slightly volatile
Total Stockholder Equity537.8 M701.1 M732.4 M
Slightly volatile
Property Plant And Equipment Net181 M172.4 M83.9 M
Slightly volatile
Accounts Payable17.7 M32.3 M21.4 M
Slightly volatile
Cash92.8 M102.4 M95 M
Slightly volatile
Non Current Assets Total379.2 M729.6 M603.9 M
Slightly volatile
Cash And Short Term Investments209.9 M162 M219.1 M
Slightly volatile
Common Stock Shares Outstanding75.8 M91.3 M76.1 M
Slightly volatile
Liabilities And Stockholders Equity676.4 M1.3 B990 M
Slightly volatile
Non Current Liabilities Total170.5 M162.4 M120.8 M
Slightly volatile
Other Current Assets54.7 M30.5 M57.4 M
Pretty Stable
Other Stockholder Equity1.7 B1.6 B969.3 M
Slightly volatile
Total Liabilities342.8 M326.5 M243.2 M
Slightly volatile
Total Current Assets307.4 M298 M359.6 M
Pretty Stable
Short Term Debt32 M18.6 M45.2 M
Pretty Stable
Net Receivables64.1 M121.2 M89.2 M
Slightly volatile
Common Stock654.9 KM738.7 K
Slightly volatile
Current Deferred Revenue513 K540 K2.9 M
Slightly volatile
Good Will250.8 M286.3 M218.7 M
Slightly volatile
Intangible Assets336.1 M262.4 M289.4 M
Slightly volatile
Long Term Debt37.6 M39.6 M154.7 M
Slightly volatile
Capital Lease Obligations114.8 M100.7 M85.2 M
Slightly volatile
Net Invested Capital729.4 M740.7 MB
Slightly volatile
Property Plant And Equipment Gross290.6 M282 M233.3 M
Slightly volatile
Capital Stock902 KM764.8 K
Slightly volatile
Non Current Liabilities Other2.1 M2.2 M9.7 M
Pretty Stable
Net Working Capital143.1 M133.9 M186.3 M
Pretty Stable

Myriad Genetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization74.7 M71.2 M30.7 M
Slightly volatile
Total Revenue431.6 M837.6 M632.3 M
Slightly volatile
Gross Profit338.4 M585.4 M487.8 M
Pretty Stable
Other Operating Expenses1.2 B1.2 B676.6 M
Slightly volatile
Research Development65.1 M113.4 M68.6 M
Slightly volatile
Total Operating Expenses971.9 M925.6 M523.4 M
Slightly volatile
Selling General Administrative487 M560 M442.2 M
Slightly volatile
Net Income Applicable To Common Shares159.7 M202.7 M163 M
Slightly volatile
Non Operating Income Net Other3.5 M3.1 M3.9 M
Slightly volatile
Interest Income1.7 M1.7 M2.5 M
Slightly volatile
Reconciled Depreciation49.7 M61.2 M66.9 M
Slightly volatile

Myriad Genetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow89.8 M140.9 M96.4 M
Slightly volatile
Depreciation64.3 M61.2 M40.2 M
Slightly volatile
Capital Expenditures31.2 M29.7 M19.1 M
Slightly volatile
End Period Cash Flow93.3 M111.9 M95.3 M
Slightly volatile
Dividends Paid288.8 M306 M366.2 M
Slightly volatile
Change Receivables51.7 M58.1 M63.4 M
Slightly volatile
Exchange Rate Changes400 K450 K490.6 K
Slightly volatile
Cash And Cash Equivalents Changes56.4 M63.5 M69.2 M
Slightly volatile
Cash Flows Other Operating47.8 M53.7 M58.6 M
Slightly volatile
Change To Operating Activities3.5 MM4.3 M
Slightly volatile
Other Cashflows From Investing Activities59.8 M67.3 M73.4 M
Slightly volatile
Change To Netincome57.1 M64.3 M70.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.32.424.3154
Slightly volatile
Dividend Yield0.220.370.2853
Slightly volatile
PTB Ratio4.162.332.5479
Slightly volatile
Days Sales Outstanding43.2749.8548.938
Slightly volatile
Book Value Per Share5.468.5110.1183
Pretty Stable
Average Payables5.6 M9.4 M9.7 M
Very volatile
Capex To Depreciation1.021.360.7417
Pretty Stable
PB Ratio4.162.332.5479
Slightly volatile
EV To Sales2.332.454.1575
Slightly volatile
Sales General And Administrative To Revenue0.880.870.8557
Slightly volatile
Research And Ddevelopement To Revenue0.130.140.2247
Slightly volatile
Capex To Revenue0.110.09730.0962
Slightly volatile
Cash Per Share1.91.532.3317
Pretty Stable
Payout Ratio44.3566.5247.3541
Slightly volatile
Current Ratio2.22.314.0525
Slightly volatile
Receivables Turnover9.747.588.7348
Slightly volatile
Shareholders Equity Per Share5.468.5110.1187
Pretty Stable
Debt To Equity0.180.170.132
Slightly volatile
Capex Per Share0.840.80.313
Slightly volatile
Average Receivables14.1 M13.4 M14 M
Slightly volatile
Revenue Per Share4.188.198.5411
Pretty Stable
Interest Debt Per Share1.071.681.5704
Pretty Stable
Debt To Assets0.130.120.0904
Slightly volatile
Graham Number4.995.2510.6987
Slightly volatile
Operating Cycle84.4780.45100
Very volatile
Price Book Value Ratio4.162.332.5479
Slightly volatile
Dividend Payout Ratio44.3566.5247.3541
Slightly volatile
Ebt Per Ebit0.730.920.9417
Very volatile
Company Equity Multiplier0.981.321.2848
Slightly volatile
Long Term Debt To Capitalization0.07510.04220.1012
Very volatile
Total Debt To Capitalization0.150.16260.1143
Slightly volatile
Debt Equity Ratio0.180.170.132
Slightly volatile
Quick Ratio2.042.153.8364
Slightly volatile
Net Income Per E B T0.871.150.7749
Slightly volatile
Cash Ratio0.930.971.0033
Slightly volatile
Days Of Sales Outstanding43.2749.8548.938
Slightly volatile
Price To Book Ratio4.162.332.5479
Slightly volatile
Fixed Asset Turnover7.413.7511.3919
Slightly volatile
Debt Ratio0.130.120.0904
Slightly volatile
Price Sales Ratio2.32.424.3154
Slightly volatile
Asset Turnover0.420.590.6146
Pretty Stable
Gross Profit Margin0.940.790.8136
Slightly volatile
Price Fair Value4.162.332.5479
Slightly volatile

Myriad Genetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap835 M1.1 B1.3 B
Very volatile
Enterprise Value790.3 M1.1 B1.2 B
Very volatile

Myriad Fundamental Market Drivers

Forward Price Earnings129.8701

Myriad Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Myriad Genetics Financial Statements

Myriad Genetics investors utilize fundamental indicators, such as revenue or net income, to predict how Myriad Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue540 K513 K
Total Revenue837.6 M431.6 M
Cost Of Revenue252.2 M264.8 M
Stock Based Compensation To Revenue 0.05  0.04 
Sales General And Administrative To Revenue 0.87  0.88 
Research And Ddevelopement To Revenue 0.14  0.13 
Capex To Revenue 0.10  0.11 
Revenue Per Share 8.19  4.18 
Ebit Per Revenue(0.31)(0.29)

Pair Trading with Myriad Genetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Myriad Stock

  0.76ME 23Andme HoldingPairCorr

Moving against Myriad Stock

  0.73DVAX Dynavax TechnologiesPairCorr
  0.45VALN Valneva SE ADRPairCorr
The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.
The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:
Check out the analysis of Myriad Genetics Correlation against competitors.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.41)
Revenue Per Share
9.245
Quarterly Revenue Growth
0.071
Return On Assets
(0.05)
Return On Equity
(0.17)
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.